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Abstract
Background: Involved or implicated in a wide spectrum of
diseases, trypsin-like serine proteases comprise well studied drug
targets and anti-targets that can be subdivided into two major
classes. In one class there is a serine at position 190 at the S1 site,
as in urokinase type plasminogen activator (urokinase or uPA)
and factor VIIa, and in the other there is an alanine at 190, as in
tissue type plasminogen activator (tPA) and factor Xa. A
hydrogen bond unique to Ser190 protease^arylamidine complexes
between OQSer190 and the inhibitor amidine confers an intrinsic
preference for such inhibitors toward Ser190 proteases over
Ala190 counterparts.
Results : Based on the structural differences between the S1 sites
of Ser190 and Ala190 protease^arylamidine complexes, we
amplified the selectivity of amidine inhibitors toward uPA and
against tPA, by factors as high as 220-fold, by incorporating a
halo group ortho to the amidine of a lead inhibitor scaffold.
Comparison of Ki values of such halo-substituted and parent
inhibitors toward a panel of Ser190 and Ala190 proteases
demonstrates pronounced selectivity of the halo analogs for
Ser190 proteases over Ala190 counterparts. Crystal structures of
Ser190 proteases, uPA and trypsin, and of an Ala190 counterpart,
thrombin, bound by a set of ortho (halo, amidino) aryl inhibitors
and of non-halo parents reveal the structural basis of the exquisite
selectivity and validate the design principle.
Conclusions: Remarkable selectivity enhancements of excep-
tionally small inhibitors are achieved toward the uPA target over
the highly similar tPA anti-target through a single atom
substitution on an otherwise relatively non-selective scaffold.
Overall selectivities for uPA over tPA as high as 980-fold at
physiological pH were realized. The increase in selectivity results
from the displacement of a single bound water molecule common
to the S1 site of both the uPA target and the tPA anti-target
because of the ensuing deficit in hydrogen bonding of the
arylamidine inhibitor when bound in the Ala190 protease anti-
target. ß 2001 Elsevier Science Ltd. All rights reserved.
Keywords: Selectivity at S1 site; H2O displacement; Urokinase
type plasminogen activator; Tissue type plasminogen activator;
Ser190/Ala190 protease; Structure-based drug design
1. Introduction
Trypsin-like serine proteases comprise a set of enzyme
targets involved or implicated in disease states. A signi¢-
cant ¢nding germane to the development of trypsin-like
serine protease inhibitors as drugs is that considerable
speci¢city can be achieved at the S1 site alone [1^3].
Such speci¢city facilitates development of small molecule
inhibitors whose low molecular weight may promote bio-
availability. Despite the high structural similarity in the S1
sites of trypsin-like serine proteases, these sites are di¡er-
entiated from one another by two important features that
can be targeted for selectivity development ^ their depth,
and the identity of residue 190. Simple amidine inhibitors
tend to be selective for Ser190 proteases (urokinase type
plasminogen activator (uPA), trypsin and tryptase) rather
than Ala190 proteases (tissue type plasminogen activator
(tPA), thrombin, and factor Xa), because of an additional
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hydrogen bond between the amidine and OQSer190 in the
former class [1].
Urokinase is a Ser190 trypsin-like serine protease impli-
cated in cancer progression [4^8], and may be a tractable
drug target for antimetastic therapy [1,2,9^14]. Therapeu-
tic inhibitors of uPA should not signi¢cantly inhibit or
disrupt the function of the closely related blood-clotting
enzyme, tPA, an anti-target [14]. Both uPA and tPA
share similar three dimensional structures [9,15], and
nearly identical S1 sites except for the side-chain of
residue 190 [1]. The preference of small amidine inhib-
itors for uPA over tPA is signi¢cant but not huge,
ranging from 7.7-fold for benzamidine to 80-fold for
4-iodobenzo[b]thiophene-2-carboxamidine [1]. Thus it
would be advantageous if the S1 recognition element of
the inhibitor could be engineered to exploit more fully
the Ser190CAla di¡erence between uPA and tPA in order
to produce small molecule sca¡olds with greater intrinsic
speci¢city toward uPA and against anti-targets such as
tPA.
One reason why the selectivity of small amidine inhib-
itors toward Ser190 proteases over Ala190 counterparts is
not larger is that a water tightly bound at S1, H2O1S1,
bridges the inhibitor with the Ala190 enzymes via hydro-
gen bonds. Often times this water also plays a similar role
in Ser190 protease complexes, where H2O1S1 as well as
OQSer190 can accept a hydrogen bond from the amidine
N1 nitrogen atom in a three-centered hydrogen bond net-
work (Fig. 1a). The N1^H2O1S1 interaction of this net-
work in many trypsin^ and uPA^amidine complexes is
long (s 3.1 Aî ), and thus either absent or auxiliary to
the OQSer190^H2O1S1 hydrogen bond. Although the N1^
OQSer190 hydrogen bond is absent in the Ala190 protease^
amidine complexes, the N1^H2O1S1 interaction is a full
hydrogen bond (Fig. 1b), typically less than 3.0 Aî in the
thrombin complexes. We reasoned that an amidine inhib-
itor capable of displacing H2O1S1 would have di¡erential
speci¢city for Ser190 versus Ala190 proteases (Fig. 1c,d),
and discovered that binding to an Ala190 anti-target
leaves the amidine N1 atom without its full complement
of hydrogen bonds (Fig. 1d). Neither OQSer190 nor H2O1S1
is present to complete the hydrogen bonding of N1 (Fig.
1d). Such a hydrogen bonding de¢cit markedly disfavors
binding because the full hydrogen bonding capacity of the
inhibitor is realized in solution with associated water mol-
ecules and/or ions.
Here we describe the remarkable speci¢city ampli¢ca-
tion (up to 220-fold) for Ser190 over Ala190 proteases
achieved from a single atom substitution (replacement of
a hydrogen ortho to the amidine with a halogen, Fig. 1c)
on a unique uPA inhibitor sca¡old. Final selectivity ratios
as high as 6700-fold are thus obtained. Crystal structures
of the Ser190 proteases, uPA and trypsin, and of the
Ala190 protease, thrombin, bound by such halo-substi-
tuted inhibitor sca¡olds are determined and compared
with one another and with corresponding complexes in-
volving non-halo counterparts. The structures and inhibi-
tion data show that the extraordinary speci¢city can be
achieved through displacement of a water bound at the
S1 site (Fig. 1c,d). Thus a one atom substitution on a
relatively non-speci¢c, small molecule inhibitor sca¡old
yields a comparably small sca¡old with vastly improved
speci¢city for the uPA target over tPA and other Ala190
anti-targets.
Fig. 1. a: Ser190 protease^APC-8696; b: Ala190 protease^APC-8696; c: Ser190 protease^APC-10302; d: Ala190 protease^APC-10302. H2O1S1 is co-
bound in all trypsin-like serine protease complexes of typical amidine inhibitors and in the apo-enzymes [1].
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2. Results
2.1. Choice of inhibitors for selectivity enhancement and of
protease^inhibitor complexes for crystallography
We chose one of the most potent, small molecule, re-
versible uPA inhibitors reported, APC-8696 [16] (Fig. 2a),
as one of the sca¡olds for selectivity augmentation
through incorporation of a halo ortho to the S1 amidine
(at the 6 position). APC-8696 belongs to a novel class
of active site-directed, small molecule inhibitors that
make a network of short hydrogen bonds at the active
site [16,17].
We also synthesized and assayed at pH 7.4 other ana-
logs of APC-8696, both indoles and benzimidazoles (Fig.
2a, Table 1a). Because the benzimidazole sca¡olds are
capable of recruiting Zn2 to mediate binding at the active
site [17], we assayed them both in the presence (Table 1d)
and absence (Table 1c) of Zn2 at pH 8.2. Finally we
studied the e¡ect on selectivity of halo substitution ortho
to the amidine of another uPA inhibitor sca¡old (APC-
7136, Table 1b, Fig. 2b).
For crystallographic visualization and comparison of
enzyme^inhibitor interactions at the S1 site we used tryp-
sin [17^21] and thrombin [17,22] as commercially avail-
able, readily crystallizable Ser190 and Ala190 protease ar-
chetypes, along with the Ser190 uPA target produced in
house [1,17]. The thrombin complex with APC-7806, the
isosteric benzimidazole analog of APC-8686, yielded larg-
er, better di¡racting crystals than did thrombin^APC-
8696, and thus the structure of thrombin^APC-7806 was
determined and is described. At physiological pH the
Fig. 2. a: APC-8696 sca¡olds; b: APC-7136 sca¡olds. Non-standard atom names are given in this and other ¢gures. Standard names are given for the
benzimidazole nitrogens in brackets.
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structures of trypsin^APC-7806 and trypsin^APC-8696 are
nearly identical, and the corresponding thrombin com-
plexes are expected to be very similar to one another.
The structures of many bound inhibitors were determined
in two or all three of the trypsin, thrombin and uPA
systems (Table 2). We determined the trypsin-bound struc-
tures of all the compounds in Fig. 2, both in the presence
and absence of Zn2 for the benzimidazoles.
2.2. Displacement of H2O1S1 through a single atom
substitution on a non-speci¢c inhibitor ampli¢es
selectivity toward Ser190 versus Ala190 proteases
Although APC-8696 (Fig. 2a) is a potent inhibitor of
uPA (Ki = 0.008 WM), it has little selectivity (only 4-fold)
against tPA (Ki = 0.035 WM, Table 1a). However, addition
of a 6-chloro, in APC-10302, dramatically ampli¢es the
selectivity toward the Ser190 protease uPA over the
Ala190 protease tPA by 220-fold, resulting in a ¢nal se-
lectivity ratio of 980 at pH 7.4, without decreasing potency
(Table 1a). Similarly, this one atom change in the inhibitor
also increases the selectivity toward the Ser190 protease
trypsin over the Ala190 counterpart thrombin by 110-
fold to a ¢nal selectivity ratio of 260 at pH 7.4 (Table 1a).
Comparison of the structures of Ser190 and Ala190
complexes of APC-10302 and APC-8696 (or of the APC-
7806 isostere) illustrates the structural basis for selectivity
enhancement resulting from displacement of H2O1S1 by
the bound inhibitor. In trypsin^APC-8696 (Fig. 3a) there
are a total of eight protease^inhibitor or protease^water^
inhibitor hydrogen bonds at the active site and oxyanion
hole, three of which are very short (shown in cyan), in-
Table 1
Inhibition constants (Ki values, WM) of inhibitors from (a) APC-7806 (benzimidazole) and APC-8696 (indole) series, pH 7.4, (b) APC-7136 series, pH
7.4, (c) APC-7806 series, pH 8.2, in the absence of Zn2, and (d) APC-7806 series, pH 8.2, in the presence of Zn2
APC# Haloa Ser190 protease Ala190 protease
uPA Trypsin Plasmin tPA Thrombin Factor Xa
(a) pH 7.4, EDTA
8 696 0.008 0.13 0.10 0.035 0.32 0.078
7 806 0.45 4.4 4.0 0.16 5.5 0.95
10 655 0.22 0.73 0.6 0.55 15 1.4
10 656 0.50 3.3 2.5 1.6 30 4.6
9 008 0.20 0.85 1.5 0.35 0.21 0.070
10 818 F 0.59 10 6.4 26 47 12
10 950 F 0.11 10 2.7 61 23 31
11 092 F 0.011 6.0 1.1 29 11 34
11 417 F 0.020 1.1 0.35 3.6 7.5 1.3
9 850 Cl 0.31 9.5 1.9 32 17 4.7
10 302 Cl 0.009 0.23 0.11 8.8 60 19
10 762 Cl 2.1 42 7.5 21 120 18
10 972 Cl 1.8 14 2.1 13 90 33
(b) pH 7.4, EDTA
7 136 3.8 3.2 6.6 12 23 24
10 484 0.077 0.28 4.4 0.29 0.15 0.41
10 605 0.33 0.61 3.2 0.19 0.53 2.2
11 922 F 0.27 2.8 5.5 1.4 0.41 0.50
11 421 C1 6.0 110 s 75 210 240 110
(c) pH 8.2, EDTA
7 806 0.29 3.7 1.7 0.65 5.5 0.95
10 656 0.18 1.3 1.0 2.7 16.0 3.4
10 818 F 0.25 13 7.5 35 110 37
10 950 F 0.16 11 31 50 s 450 s 450
11 092 F 0.025 5.5 0.95 47 14 25
10 762 Cl 0.85 33 3.9 45 260 50
10 972 Cl 0.49 12 2.3 31 160 55
(d) pH 8.2, Zn2
7 806 0.30 0.15 1.0 1.1 0.45 0.43
10 656 0.39 0.026 0.48 5.5 0.55 0.37
10 818 F 0.55 10 4.5 s 450 1.2 2.6
10 950 F 2.0 2.3 9.9 370 1.3 1.7
11 092 F 0.14 8.0 2.3 s 450 0.60 1.2
10 762 Cl 8.5 21 60 s 450 250 21
10 972 Cl 6.5 0.65 2.7 160 55 4.3
Values in bold indicate that competitive inhibition was demonstrated and Ki values determined rigorously by varying both the substrate and the inhibi-
tor concentrations as described [1,17]. The other Ki values were determined at one substrate concentration (per enzyme) set at or near the determined
Km value, while the inhibitor concentration was varied [1,17].
aOrtho to the amidine, Fig. 2a.
CHBIOL 148 24-10-01 Cyaan Magenta Geel Zwart
1110 Chemistry & Biology 8/11 (2001) 1107^1121
volving the hydroxyl of Ser195, the phenolate of the in-
hibitor (O6P) and a water co-bound in the oxyanion hole
(H2Ooxy). In thrombin^APC-7806 the inhibitor is also
¢rmly anchored at the active site and oxyanion hole by
an array of short and normal hydrogen bonds (Fig. 3b). A
summary of hydrogen bond parameters at the active site
for over 150 complexes involving the inhibitors of this
study is available upon request.
The S1 site hydrogen bonding interactions for trypsin^
APC-8696 are typical for trypsin^amidine inhibitor com-
plexes [1,18]. There are two hydrogen-bonded salt bridges
from the amidine to the Asp189 carboxylate, one hydro-
gen bond from N2 to OGly219, and two partial hydrogen
bonds, N1^OQSer190 and N1^H2O1S1, in a three-centered
hydrogen bonding network (Figs. 1a and 3a). H2O1S1 is
tightly bound in trypsin^APC-8696 (B = 13 Aî 2 at pH 8.0)
and in other protease^amidine complexes (Table 3b). It
receives long hydrogen bonds from N1 and from OQSer190
and donates hydrogen bonds to OTrp215 and to OVal227
(Fig. 3a).
The interactions at the S1 site of the analogous Ala190
complex, thrombin^APC-7806, are also typical (Fig. 3b,
Table 3). The OQSer190^amidine and OQSer190^H2O1S1 hy-
drogen bonds in the trypsin complex are absent in the
Ala190 thrombin counterpart. H2O1S1 makes only three
hydrogen bonds in thrombin^APC-7806, to OVal227, to
OTrp215, and from N1 (Table 3b).
Introduction of a chloro ortho to the amidine in APC-
10302 (Fig. 2a) results in displacement of H2O1S1 upon
inhibitor binding to trypsin (Fig. 4a) and to thrombin
(Fig. 4b). The exclusion of H2O1S1 from the protease com-
plexes eliminates the N1^H2O1S1 hydrogen bond (Fig. 4).
The two partial hydrogen bonds (N1^OQSer190 and N1^
H2O1S1) of the three-centered hydrogen bond network in
Fig. 3. a: Structure and associated (2MFoM3MFcM), Kc map of P3121 (form c) trypsin^APC-8696, pH 7.07, 1.37 Aî resolution, contoured at 1.0 c (beige)
and 2.4 c (red). Residue names are labeled white, selected atom names light yellow, and H2O1S1 light blue. Short hydrogen bonds at the active site are
cyan, and hydrogen bonds involving H2O1S1 at the S1 site are cyan. The directionalities of the hydrogen bonds involving OQSer190 and ORTyr228 can be
inferred from the following: a well ordered water (not shown) donates one proton to OAla183, and the other to ON1Asp189. This water must therefore ac-
cept the hydrogen bond from ORTyr228. It also follows that OQSer190 donates a (partial) hydrogen bond to ORTyr228, and to H2O1S1. In addition to the
hydrogen bonds accepted from H2O1S1, the carbonyl oxygens of residues 215 and 227 also accept L-sheet hydrogen bonds, with better angular compo-
nents, from the peptide nitrogens of residues 227 and 215, respectively, in these and other structures. b: Structure and (2MFoM3MFcM), Kc map for throm-
bin^APC-7806, pH 8.68, 1.75 Aî resolution.
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trypsin^APC-8696 are replaced with a full hydrogen bond
(N1^OQSer190) in trypsin^APC-10302, where the amidine
still has a su⁄cient complement of hydrogen bonds. But
removal of the sole N1^H2O1S1 hydrogen bond in throm-
bin^APC-7806 by displacement of H2O1S1 in thrombin^
APC-10302 leaves the amidine H1 atom without a conven-
tional hydrogen bond acceptor (Fig. 4b). The loss of this
hydrogen bond, observed in thrombin^APC-7806 and in-
ferred in APC-8696 complexes of thrombin, factor Xa and
tPA, results in a sizable decrease in potency of APC-10302
compared to APC-8696 for thrombin, factor Xa, and tPA,
by 190-, 240-, and 250-fold, respectively (Table 1a).
2.3. Bound APC-10302 forms direct hydrogen-bonded salt
bridges with Asp189
The binding to uPA of inhibitors like APC-8696 that
form short hydrogen bonds at the active site is atypical for
amidine inhibitors of trypsin-like serine proteases in that
there are no direct hydrogen bonds from the amidine to
Asp189 at the S1 site. Instead a bound water, H2O2S1,
bridges the amidine with one of the carboxylate oxygens
of Asp189 [17] (Fig. 5a), emphasizing the ¢rm anchorage
of the inhibitor at the active site via the intricate short and
normal hydrogen bond network.
Table 2
Complexes for which the structure of a bound inhibitor was determined
in multiple enzymes
X APC# Resolution (Aî )
uPA Trypsin Thrombin
(a) APC-8696 sca¡old
7 806 1.90 1.43 1.73
8 696 1.73 1.41
10 655 1.78 1.58 2.00
F 11 417 1.86 1.50
F 11 092 1.80 1.46
F 10 950 1.64 1.45
Cl 10 302 1.50 1.50 1.81
Cl 9 850 1.84 1.43 1.60
(b) APC-7136 sca¡old
7 136 1.56 1.37 1.50
10 484 1.60 1.37 1.70
10 605 1.83 1.38 1.41
F 11 922 2.20 1.50 2.05
Cl 11 421 1.75 1.40 1.67
X is the halo group ortho to the amidine, Fig. 2a. Rcryst and other crys-
tallographic di¡raction and re¢nement statistics for a subset of these
structures are given in Table 4. All of the structures were determined at
physiological pH values. For complexes involving structures at multiple
pH values, the resolution of the best di¡racting crystal is given.
Fig. 4. a: Structure and (2MFoM3MFcM), Kc map for trypsin^APC-10302, pH 9.05, 1.50 Aî resolution. b: Thrombin^APC-10302, pH 9.0, 1.81 Aî resolu-
tion. Because of the poor Ki and limited solubility of APC-10302 in the Ala190 thrombin anti-target, the inhibitor is bound with partial occupancy
(0.80). The chloro makes contacts with CQ1Val213 (3.25 Aî ), CLAla190 (3.70 Aî ), OTrp215 (3.83 Aî ), and CKGly226 (4.14 Aî ). Hydrogen bonds involving the in-
dole N3 atom are not short, as in thrombin^APC-7806.
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An unexpected di¡erence between the structures of
uPA^APC-8696 and uPA^APC-10302 is the displacement
from the latter complex of the amidine^Asp189 bridging
water (H2O2S1), in addition to displacement of the other
S1 water (H2O1S1) that is common to the uPA, trypsin,
and thrombin complexes of APC-8696. Displacement of
these waters results in direct amidine^Asp189 carboxylate
hydrogen-bonded salt bridges in uPA^APC-10302 (Fig.
5b).
2.4. Structural di¡erences at the S1 site incurred by
incorporation of the chloro ortho to the amidine
In the APC-10302^protease complexes the indole por-
tion of the inhibitor is oriented somewhat di¡erently from
that in APC-8696 counterparts, and is 0.8^1.1 Aî deeper in
the S1 site, placing the chloride well into the cavity pro-
duced by removal of H2O1S1 (Fig. 5c). In uPA^APC-
10302 the Asp189 side-chain is shifted from its position
in uPA^APC-8696, by V0.5 Aî toward the inhibitor, to
form hydrogen bonds with the amidine in uPA^APC-
10302 (Fig. 5c).
The large 6-chloro group in APC-10302 sterically favors
a more non-planar indole^aryl system. There is a signi¢-
cant change in the indole^aryl dihedral angle, e.g. from
0 þ 7‡ in trypsin^APC-8696 to 29 þ 2‡ in trypsin^APC-
10302 (Table 3a), incurred by the chloro substitution
and by the change in position and orientation of the in-
hibitor. In thrombin^APC-10302, however, the amidine is
coplanar with the indole (dihedral angle =31 þ 5‡), allow-
ing the H1 amidine proton to make a hydrogen bond of
2.7 Aî with the chloro. This hydrogen bond is made at the
cost of steric strain from close intramolecular contacts
resulting from the planarity, estimated by ab initio MO
calculations [1] to be 5.0 kcal/mol. The relatively short
N1^ON1Asp189 and N2^ON2Asp189 hydrogen bonds (2.67 Aî
and 2.65 Aî , Table 3a), and the diagonal N1^ON2Asp189
hydrogen bond (3.15 Aî ) may all serve to compensate for
the absence of a more favorable, conventional hydrogen
bond involving the amidine H1 atom.
Table 3
Hydrogen bond lengths and angles, inhibitor dihedrals, and bound water B-factors at the S1 site of uPA, trypsin and thrombin complexes of APC-8696
analogs
(a) Parameters not involving bound waters



















Urokinase Cl 10 302 6.5 3.13 2.73 2.96 3.25 2.75 131 2.85 3.34 31 1
F 11 092 6.5, 8.2 3.37(03) 2.70(01) 3.15(10) 3.23(08) 2.83(01) 117(4) 3.12(00) 2.93(01) 4(2) 2
Trypsin H 8 696 4.6^10.9 2.98(09) 2.68(06) 2.93(08) 3.33(09) 2.95(09) 127(5) 2.78(07) 0(7) 17
F 10 818 4.6^10.9 2.96(09) 2.65(05) 2.88(07) 3.27(09) 2.89(04) 134(3) 2.72(09) 2.93(05) 18(4) 8
Cl 10 302 4.4^10.7 2.90(08) 2.70(03) 2.89(05) 3.24(03) 2.84(09) 131(3) 2.67(09) 3.23(11) 29(2) 8
Thrombin H 7 806 7.8^10.8 2.95(11) 2.70(12) 3.04(14) 3.56(12) 316(7) 5
Cl 10 302 7.8^9.0 2.67(08) 2.61(02) 2.65(16) 3.15(10) 31(5) 2
(b) Parameters involving H2O1S1

















Urokinase F 10 950 6.5 3.49 170 2.92 3.13 3.52 3.02 28 2.76 1
Trypsin H 8 696a 4.6^10.9 3.30(20) 141(5) 3.23(14) 2.87(11) 3.16(10) 2.78(08) 29(9) 17
Thrombin H 7 806 7.8^10.8 2.94(03) 151(4) 2.96(11) 3.11(11) 15(5) 5
(c) Parameters involving H2O-mediated H-bonds with Asp189

















Urokinase H 8 696, 7 806 6.5 2.54(08) 2.62(01) 2.57(03) 3.00(07) 3.04(03) 103(1) 2.88(03) 321(1) 2
Urokinase F 10 950 6.5 3.06 2.68 2.53 2.67 3.30 115 3.02 319 1
Urokinase F 11 417 6.5 2.84 2.49 2.48 2.76 2.76 133 3.25 36 1



















Urokinase H 8 696, 7 806 6.5 2.82(03) 146(5) 3.08(05) 3.08(03) 3.12(11) 27(4) 32(4) 2
Urokinase F 10 950 6.5 3.49 170 2.92 3.13 3.52 28 16 2.76 3.08 1
Urokinase F 11 417b 6.5 3.27 143 2.76 3.04 3.35 25 7 2.52 2.77 1
An expanded version of this table containing a summary of the S1 site parameters for 185 structures involving both the APC-8696 and APC-7136 scaf-
folds is available upon request.
aIn some cases, where N1^H2O1S1 is long (s 3.4 Aî ), H2O1S1 makes a hydrogen bond with the Z system of Tyr228.
bThere is a three-centered H-bond network involving F, H2O1S1 and OQSer190. In this structure OQSer190 does not donate a hydrogen bond to ORTyr228
(distance = 3.25 Aî ) as it does in many other uPA and trypsin structures.
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2.5. Absence of waters (H2Ooxy and H2Odistal) bound at the
oxyanion hole of uPA and trypsin complexes of
APC-10302
Replacement of bound APC-8696 (or APC-7806) by
APC-10302 in uPA or trypsin is associated with a confor-
mational change in Ser195 which shifts OQSer195 by over
1 Aî into the oxyanion hole. The shift in OQSer195 breaks the
N3^OQSer195 and NO2His57^OQSer195 hydrogen bonds and
displaces H2Ooxy and H2Odistal (Fig. 4a; Fig. 5b). Loss
of H2Ooxy upon binding of APC-10302 to uPA converts
the three-centered short hydrogen bonding array in uPA^
APC-8696 to a single OQSer195^O6P hydrogen bond of nor-
mal length (2.75 Aî ) in uPA^APC-10302.
2.6. Favorable interactions of the uPA-bound APC-10302
sca¡old
A total of four ordered waters (H2O1S1, H2O2S1,
H2Ooxy, and H2Odistal) present in uPA-8696 are absent in
Fig. 5. Structure and (2MFoM3MFcM), Kc map for (a) uPA^APC-8696, pH 6.50, 1.73 Aî resolution, and (b) uPA^APC-10302, pH 6.50, 1.50 Aî resolution.
c: Superimposed structures of uPA^APC-8696 and uPA^APC-10302.
CHBIOL 148 24-10-01 Cyaan Magenta Geel Zwart
1114 Chemistry & Biology 8/11 (2001) 1107^1121
uPA^APC-10302. These waters appear well oriented
through the many associated hydrogen bonds (Fig. 5a),
and the ¢rst three have relatively low B-factors. The en-
tropy change upon the displacement of some of these
waters may be close to maximal, 2.0 kcal/mol per water
[23].
Displacement of H2O2S1 by bound APC-10302 results
in a conversion of H2O2S1-bridged amidine^Asp189 hy-
drogen bonds in uPA^APC-8696 (Fig. 5a) to direct and
presumably stronger ones in uPA^APC-10302 (Fig. 5b).
Also in the latter complex, ON1Asp189 has a full comple-
ment of hydrogen bonds, whereas in the H2O2S1-bridged
binding mode of uPA^APC-8696, it does not (Fig. 5a).
The indole sca¡olds, like APC-10302, exhibit signi¢-
cantly greater intrinsic a⁄nity over the benzimidazole
counterparts toward all the proteases in Table 1. Conver-
sion of the non-halo (APC-7806), the 6-£uoro (APC-
10818) and 6-chloro (APC-10762) benzimidazoles to the
corresponding indoles (APC-8696, APC-11417, and
APC-10302, respectively) signi¢cantly increases inhibitor
potency for all enzymes in Table 1a by average factors
of 27, 13 and 82, respectively. Increased potency of the
indole sca¡old re£ects, in part, a less costly change in
internal energy to convert the lowest energy solution con-
former to the binding conformer than for the benzimida-
zole [17]. The benzimidazole conformer with the nitrogen
at the 1-position unprotonated (the non-binding tautomer)
is more stable in the unbound state than the other tauto-
mer due to withdrawal (by resonance) of electrons from
the nitrogen at position 1 by the amidine. The indole, with
only one possible internal hydrogen bond possible, is
locked into the binding conformation. The ampli¢cation
of this a⁄nity di¡erence between the indole and benzimi-
dazole sca¡olds by the 6-chloro group is thought to occur
through its donation of electrons by resonance to the car-
bons adjacent to the nitrogen at position 3 and withdrawal
of electrons by induction from the nitrogen at position 1
of the benzimidazole. Higher pKa values of the amidine
and phenol of the indoles may also increase hydrogen
bond strengths at the S1 and active sites.
2.7. Dual binding potential of ortho (£uoro, amidino) aryl
inhibitor sca¡olds in uPA
Replacement of the chloro of uPA-bound APC-10302
with a £uoro in the APC-11417 isostere converts a direct
hydrogen-bonded amidine^Asp189 S1 binding mode into
one mediated by two waters (H2O1S1 and H2O2S1). In this
Fig. 6. a: Structure and (2MFoM3MFcM), Kc map for uPA^APC-11092, 1.80 Aî resolution. The long N1^ON2Asp189 and N2^ON2Asp189 interactions (3.17 Aî
and 3.40 Aî , respectively, at pH 6.5) are shown in yellow and transparent light yellow, respectively. b: Structure and (2MFoM3MFcM), Kc map for uPA^
APC-10950, 1.64 Aî resolution. The H2O1S1^F hydrogen bond (2.76 Aî ) is formed at the expense of the H2O1S1^OTrp215 interaction, the length of which
increases from 3.07 Aî in uPA^APC-8696 to 3.52 Aî in uPA^APC-10950 (Table 3c).
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water-mediated S1 binding mode, APC-11417 sits higher
in the S1 site, like the uPA-bound parent compound,
APC-8696. In uPA^APC-11417 H2O1S1 donates a rela-
tively short hydrogen bond (2.52 Aî ) to the £uoro (Table
3c).
Such a change in binding can also be e¡ected by a
change in the inhibitor group probing S1P in cases where
a £uoro is ortho to the amidine. Thus APC-11092, with a
methylcyclohexyl ether group ortho to the phenol hydrox-
yl, makes direct hydrogen-bonded salt bridges with
Asp189 (Fig. 6a), whereas APC-10950, with an isobutyl
ether group ortho to the phenol hydroxyl, makes water-
mediated hydrogen bonds with Asp189 (Fig. 6b). In the
water-mediated S1 binding mode of APC-10950, the ether
oxygen does not make hydrogen bonds (Fig. 6b), whereas
in the direct amidine^Asp189 hydrogen-bonded mode of
APC-11092, this oxygen receives a hydrogen bond from
NO2His57 (Fig. 6a). While the relatively large S1 site of uPA
is associated with two S1 binding modes of 6-£uoro-5-
amidinoindole or 6-£uoro-5-amidinobenzimidazole inhibi-
tors, depending on distal interactions at S1P, only the di-
rect hydrogen-bonded amidine^Asp189, H2O1S1-displaced
mode of binding of such inhibitors is compatible with the
smaller S1 site of trypsin.
2.8. E¡ects on potency, selectivity, and structure incurred
by incorporating a halo ortho to the amidine of another
sca¡old
Another uPA inhibitor sca¡old, APC-7136 (Fig. 2b),
can be considered an analog of APC-8696 in which the
¢ve-membered ring is opened: in APC-7136 an amide
group connects the phenol with the S1 phenylamidine
(compare Fig. 2a and b). The APC-7136 sca¡old exhibits
two distinct active site binding modes depending on both
the inhibitor and the protease (Fig. 7a,b).
In APC-11421 and APC-11922 (Fig. 2b) there is a
chloro or £uoro, respectively, ortho to the amidine, as
for the halo-substituted APC-8696 analogs, described
above. Incorporation of the £uoro in APC-11922 does
not result in Ser190/Ala190 protease selectivity; APC-
11922 exhibits about the same potency toward all pro-
teases in Table 1 (within a factor of 20) as the parent,
APC-10605. The crystal structures of the uPA, trypsin
and thrombin complexes of APC-11922 show that
H2O1S1 is not displaced from the S1 site (Fig. 7a) in any
of these three systems. In each complex the £uoro makes
an unusually short hydrogen bond with the retained water
(2.5^2.7 Aî ). These structures demonstrate that lack of se-
Fig. 7. a: Structure and (2MFoM3MFcM), Kc map of trypsin^APC-11922, 1.50 Aî resolution. For the major inhibitor conformer (opaque sticks) there is a
hydrogen bond between the inhibitor phenol (O6P) and NO2His57, and a short O6P^OQSer195 hydrogen bond. b: Structure and (2MFoM3MFcM), Kc map of
uPA^APC-11421, 1.75 Aî resolution. In this and all other uPA complexes of the APC-7136 analogs in Fig. 2b, the phenol hydroxyl is at or near the
oxyanion hole, receiving hydrogen bonds from NGly193 and from the inhibitor NH amide group. In many trypsin and thrombin complexes the inhibitor
is discretely disordered between the two binding modes in (a) and (b).
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lectivity is correlated with failure of the £uoro to displace
H2O1S1.
Displacement of H2O1S1 by the larger chloro group is
observed in the trypsin and uPA complexes of APC-11421
(Fig. 7b), and expected in the other APC-11421 complexes
of the proteases in Table 1. Unlike the ortho (halo, ami-
dino) benzimidazoles or indoles the ortho (chloro, amidi-
no) phenyl compound, APC-11421, does not show general
selectivity for Ser190 versus Ala190 proteases ; it is mod-
erately selective for uPA only, by 35-fold over tPA. Re-
duced a⁄nity for Ala190 proteases like tPA is expected to
occur for the same reason as for APC-10302, through a
hydrogen bonding de¢cit involving the bound amidine
when H2O1S1 is displaced. However reduction in binding
to a particular protease, either Ser190 or Ala190, can also
occur due to loss of favorable interactions at the active
site, especially when the inter-relationship of the S1 and
active sites prohibits optimal enzyme^inhibitor interac-
tions at both loci simultaneously, as observed in trypsin^
APC-11421.
The S1^active site separation is smaller in trypsin than
in uPA byV0.5 Aî . Thus, whereas in uPA^APC-11421 the
phenol hydroxyl (O6P) occupies the oxyanion hole, in the
trypsin complex O6P is shifted out of it by 0.7 Aî . The O6P^
OQSer195 hydrogen bond (2.75 Aî ) is therefore not as short
as in the uPA complex (2.39 Aî ). Van der Waals interac-
tions of the inhibitor iodide are also poorer in the trypsin
complex. This comparison emphasizes the observation
that structural features in addition to the side-chain of
residue 190 di¡erentiate the S1 sites of trypsin-like serine
proteases and constitute a unique signature of each pro-
tease [1]. The depth, width, and spatial relationship of the
S1 and active site di¡er signi¢cantly from one protease to
another, even when the local sequences that form these
sites are the same [1].
2.9. Halo selectivity switch and Zn2-mediated binding of
benzimidazole sca¡olds
The potency at pH 8.2 of the non-halo benzimidazoles
is essentially unaltered by Zn2, toward uPA, tPA and
plasmin, or improved, by up to 50-fold, toward trypsin,
thrombin and factor Xa (Table 1c,d). Crystallographically
determined Zn2-mediated binding modes have been de-
scribed for trypsin and thrombin [17], and determined for
all the trypsin complexes of the halo and non-halo benzi-
midazoles in Fig. 2a. Zn2 can exert pronounced e¡ects on
the activity of the 6-halo benzimidazoles, but these e¡ects
can be adverse as well as bene¢cial. The dramatic selectiv-
ity for uPA over tPA in the absence of Zn2 (by up to
1900 at pH 8.2, Table 1c) is preserved in the presence of
Zn2 (by up to s 3200, Table 1d). However the selectivity
of the 6-£uoro-5-amidinobenzimidazoles against the other
Ala190 proteases, thrombin and factor Xa is lost due to
increased a⁄nity (by up to 350-fold) in the presence of
Zn2, possibly through retention of H2O1S1. While the
6-£uoro analogs are selective against only one of the
Ala190 proteases (tPA) in the presence of Zn2, the
6-chloro analogs are selective against two of them (tPA
and thrombin) (Table 1d). The potential participation
and often signi¢cant e¡ect of Zn2 on the activity of ben-
zimidazole inhibitors that can operate in a Zn2-depen-
dent mode introduces another diverse inhibitor binding
manifold along with unique opportunities to consider for
in vivo inhibition.
3. Discussion
3.1. Selectivity enhancement through displacement of a
bound water at the S1 site via a one atom substitution
Displacement of a tightly bound water molecule by a
rigid inhibitor group is a common strategy to increase
inhibitor a⁄nity [24], due to the increase in entropy (up
to 2.0 kcal/mol [23]) upon the release of the water. If the
water is present in a target but absent in an anti-target an
increase in selectivity is thereby achieved. Thus, displace-
ment by an appropriate inhibitor group of a tetrahedrally
hydrogen-bonded water present in HIV protease but ab-
sent in related aspartic acid proteases such as pepsins
proved to be a successful strategy in the design of potent,
bioavailable HIV protease inhibitors [25,26].
We are unaware, however, of any previous examples
where inhibitor speci¢city is achieved from displacement
of a tightly bound water that is conserved in both the
target and the anti-target. Our successful design of inhib-
itors highly selective for the S1 site of uPA relies on the
fact that the enzyme^H2O1S1^inhibitor interactions are
disposable in the Ser190 uPA target but essential in the
Ala190 tPA anti-target for these types of inhibitors. Thus
the selectivity enhancements we achieved result primarily
from a large decrease in inhibitor a⁄nity toward the anti-
target, rather than from an increase toward the target.
Through a single atom substitution we achieved in-
creases in selectivity toward the uPA Ser190 protease tar-
get over the Ala190 protease anti-targets tPA, thrombin,
and factor Xa, of 220-, 170-, and 220-fold, respectively, at
pH 7.4. Final selectivity ratios as high as 6700 were thus
realized. The displacement of a ¢rmly bound water
(H2O1S1) and ensuing loss of a critical hydrogen bond
from the inhibitor amidine in the Ala190 protease com-
plexes is a novel and e¡ective strategy for achieving excep-
tional selectivity toward uPA and other Ser190 protease
targets over Ala190 counterparts.
In many uPA, trypsin and other Ser190 protease^inhib-
itor complexes, H2O1S1, OQSer190, and an amidine nitrogen
(N1) participate in a three-centered hydrogen bonding net-
work (Fig. 1a). Upon displacement of H2O1S1 from the
Ser190 protease complexes by the halo substituent of the
bound inhibitor, the amidine still has a su⁄cient comple-
ment of hydrogen bonds: the two partial hydrogen bonds,
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N1^H2O1S1 and N1^OQSer190, are replaced with a single
full hydrogen bond, N1^OQSer190 (Fig. 1c). In Ala190 pro-
teases such as tPA, thrombin, and factor Xa, displacement
of H2O1S1 greatly disfavors inhibitor binding, because it
leaves one of the protons on N1 without a conventional
hydrogen bond (Fig. 1d).
By exploiting a subtle di¡erence between the highly sim-
ilar S1 sites of Ser190 and Ala190 proteases the design
principle achieves potent, selective inhibitors with only a
modest increase in molecular weight, thereby increasing
the potential for bioavailability. A focus on small S1 rec-
ognition elements is also compatible with the design of
relatively rigid inhibitors that are not as susceptible to
the detrimental loss of conformational entropy upon bind-
ing as are larger, more £exible inhibitors.
3.2. Speci¢city enhancement by displacement of H2O1S1
from the Ala190 proteases only
The relatively small atom size and bond length involving
£uoro allow its incorporation at the relatively large S1 site
of uPA without H2O1S1 displacement in some of the com-
plexes such as uPA^APC-11417 and uPA^APC-10950
(Fig. 6b). However, APC-11417 and APC-10950 still
show speci¢city for Ser190 over Ala190 proteases, up to
450-fold for APC-10950 toward uPA over tPA, and up to
380-fold for APC-11417 toward uPA over thrombin at pH
7.4 (Table 1a). In the tPA and thrombin complexes these
inhibitors are expected to make direct hydrogen bonds
with Asp189 (the prevalent mode for trypsin-like serine
proteases), involving displacement of H2O1S1 by the £uo-
ro, as observed in the structures of the corresponding
trypsin complexes. Thus, to generate Ser190/Ala190 pro-
tease selectivity, H2O1S1 needs not be displaced in the
Ser190 enzyme, only in the Ala190 counterparts.
The crystal structures and Ki values involving the phe-
nylamidine APC-7136 sca¡old demonstrate the impor-
tance of H2O1S1 displacement for speci¢city generation
by ortho (£uoro, amidino) phenyl inhibitors. The £uoro
analog, APC-11922, shows no speci¢city for Ser190 over
Ala190 proteases, similar to the parent analog, APC-10605
(Table 1b). The crystal structures of the APC-11922 com-
plexes of the Ser190 proteases trypsin and uPA and of the
Ala190 counterpart thrombin show that this lack of spe-
ci¢city re£ects failure to displace H2O1S1 in these com-
plexes.
3.3. Preference for Ser190 versus Ala190 proteases of
small, S1-directed amidines versus those directed
to both the S1 and active sites
Whereas a general, modest preference of small, non-ac-
tive site-directed amidine inhibitors for Ser190 proteases
over Ala190 counterparts was observed and attributed to
an additional, OQSer190^amidine hydrogen bond in the for-
mer complexes [1], this preference is not apparent in the
active site-directed, non-halo inhibitors of this study. In-
teractions at the active site or elsewhere can mask the
e¡ects at S1. For example, many of the indole or benzi-
midazole amidine inhibitors in this study make a short
hydrogen bond with H2Ooxy [17]. Because H2Ooxy binds
to apo-thrombin but not to apo-trypsin [17], there is a less
favorable entropy change, involving co-binding and order-
ing of H2Ooxy, accompanying binding of the active site-
directed inhibitors to trypsin than to thrombin. Opposing
free energy changes at di¡erent loci provide a rationale for
why the selectivity trends for simple amidine inhibitors [1]
do not generally translate to the more elaborated, active
site-directed non-halo arylamidine inhibitors of this study
(Table 1).
3.4. E¡ect on binding to trypsin versus uPA of ortho halo
substitution on the two inhibitor sca¡olds
In uPA an enthalpy gain accompanies the binding of
APC-10302 over uPA-8696 through formation of direct
hydrogen bonds, whereas in trypsin there is no such
change because both inhibitors make direct hydrogen
bonds with Asp189. There is also no entropy gain in tryp-
sin from displacement of H2O2S1, which is absent in
all trypsin complexes. The net e¡ect of the changes in
interactions at S1 (and elsewhere) between binding of
APC-10302 and APC-8696 on inhibitor a⁄nity is small
(6 2-fold) for both uPA and trypsin.
Similar considerations apply to the APC-7136 sca¡old
(Fig. 2b), except both halo and non-halo analogs make
typical hydrogen-bonded salt bridges at the S1 site of
uPA (and of trypsin and thrombin). The active site bind-
ing modes of the APC-10605 parent and the APC-11421
chloro analog are very similar in uPA, but the Ki for APC-
11421 is 18-fold higher. This comparison suggests that the
net e¡ect of displacement of H2O1S1 by the halo, in the
absence of other changes at S1 or at the active site, is
somewhat unfavorable.
3.5. Exploiting interactions at S1P for potency and
selectivity
The sca¡olds of this study are ideal for probing and
optimizing interactions at the S1P site from aromatic
(Figs. 3^5) or aliphatic (Fig. 6) substituents. The ether link-
ages in compounds like APC-11092 (Fig. 6a) and APC-
10950 (Fig. 6b) o¡er the opportunity for a library approach
to optimization of S1P-directed substituents. Thus APC-
11092, developed by this approach, is v 100-fold selective
for uPA against all other proteases in Table 1.
Even single halo atom substituents directed at S1P in the
phenylamidine sca¡old can modulate speci¢city through
di¡erential interaction with Cys42^Cys58 disul¢de at S1P.
Although this disul¢de is a conserved feature of trypsin-
like serine proteases, its precise location and orientation
relative to the active and S1 sites are a distinguishing fea-
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ture of each protease. Thus the bromo group in APC-
10484 increases potency by 150-fold toward thrombin
but by only 1.5-fold toward plasmin (Table 1b).
3.6. Cooperativity of S1, active site, and distal binding
elements in determining inhibitor potency and bound
structure
Modulation of the size of the halo group or of the size
and character of an alternate group (such as OH, CH3, or
OCH3 [27]) ortho to the S1 amidine could be a powerful
way of tuning selectivity toward individual Ser190 targets
based on subtle di¡erences in the size of their S1 sites. The
Ki values and corresponding structures of the complexes
of this study show how subtle changes in depth, width,
and spatial relationship of the S1 and active sites can
a¡ect inhibitor potency. Thus, while dramatic selectivity
can be achieved against Ala190 proteases through dis-
placement of H2O1S1, such a change can also compromise
binding to individual members of the Ser190 protease class
because of their unique S1 sites, as observed for APC-
11421, which retains reasonable a⁄nity (6.0 WM) for
uPA only. Similarly, cooperative interplay of interactions
at the S1, S1P and active sites results in high a⁄nity (11
nM) and high selectivity (v100-fold) of APC-11092 to-
ward uPA only. Notable selectivity within the set of
Ser190 proteases (up to 57-fold), and within the set of
Ala190 proteases (up to 750-fold) is also observed for
some of the benzimidazoles in the Zn2-mediated active
site binding mode.
From crystallographic study of several similar inhibitors
in multiple proteases, we observed a remarkable diversity
in inhibitor binding, underscoring the importance of high-
throughput crystallography for structure-based develop-
ment of selective inhibitors. We discovered many distinct
active site and S1 site hydrogen bonding modes, in which
the relative location of a particular inhibitor sca¡old at
these sites could vary by over 1 Aî . Observation of multi-
ple, distinct binding modes in each of the lead sca¡olds
demonstrates tight coupling of the S1, S1P and active sites
and of the corresponding inhibitor recognition elements in
determining the bound structure. Subtle di¡erences in
these structural features among the proteases can impart
inhibitor discrimination and thus a¡ord opportunities for
engineering selectivity.
4. Signi¢cance
Drug development of inhibitors of trypsin-like serine
proteases involved in pathogenesis can provide therapy
for associated disease states. Recently we reported an in-
trinsic preference of arylamidine inhibitors toward Ser190
trypsin-like serine proteases over Ala190 counterparts, at-
tributed to an additional hydrogen bond between the ami-
dine and OQSer190 in the former protease class. Here we
have shown speci¢cally how to harness the Ser/Ala190
di¡erence to amplify this selectivity as high as 220-fold,
with a one atom substitution on the S1 binding element of
a unique uPA inhibitor sca¡old. Overall selectivity values
as high as 6700 are thus achieved.
In Ser190 protease complexes the inhibitor amidine N1
atom donates a hydrogen bond to OQSer190, and may also
donate a hydrogen bond to H2O1S1. Upon displacement
of H2O1S1 from the Ser190 protease complexes by the halo
of the bound inhibitor the amidine still has a satisfactory
complement of hydrogen bonds: in cases where H2O1S1
participates in a three-centered hydrogen bond network
the two partial hydrogen bonds, N1^H2O1S1 and N1^
OQSer190, are replaced with a single full hydrogen bond,
N1^OQSer190. In corresponding inhibitor complexes of
Ala190 counterparts such as tPA, thrombin and factor
Xa, displacement of H2O1S1 seriously compromises inhib-
itor binding because it leaves one of the protons on N1
without a conventional hydrogen bond.
A focus on structural di¡erences at the S1 site for se-
lectivity engineering allows development of exceptionally
small inhibitors to increase the potential for bioavailabil-
ity. Thus we have designed and developed low nanomolar,
low molecular weight inhibitors, remarkably selective for
the Ser190 protease cancer target, uPA, and against the
Ala190 anti-targets tPA, thrombin, and factor Xa. The
unique basis of speci¢city, displacement of a conserved
water ¢rmly bound at the same location of the S1 site of
both the target and the anti-target to remove a critical
hydrogen bond in the anti-target, exploits a subtle di¡er-
ence between closely related and highly structurally similar
enzymes. This selectivity switch for discriminating between
uPA and tPA and between other Ser190 targets and
Ala190 anti-targets is a unique and powerful tool for
structure-based drug design of potent selective protease
inhibitors.
5. Materials and methods
Synthesis of inhibitors is described in detail elsewhere [16,27].
5.1. Enzymology
Ki values were determined at pH 7.4 or at 8.2 in the presence of
100 WM Zn2 or 1.0 mM EDTA as described [1,16,17,28]. Ap-
parent inhibition constants, KiP values, were calculated from the
velocity data collected at various inhibitor concentrations using
the software package BatchKi (developed and provided by Dr.
Petr Kuzmic, Biokin Ltd., Madison, WI, USA) using method-
ology similar to that described for tight binding inhibitors [29].
KiP values were converted to Ki values by the formula Ki = KiP/
(1+S/Km).
5.2. Crystallography
Production and crystallization of mutagenically deglycosylated
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low molecular weight uPA have been described [1]. X-ray di¡rac-
tion data were collected with an R-AXIS IV image plate as de-
scribed [1,17]. The completeness of each data-set before rejection
of weak re£ections (Fo/c6 1.7^2.0) was s 98.5% for trypsin crys-
tals and s 96% for the lower symmetry thrombin and uPA crys-
tals. Initial structures were determined by analysis of
(MFoM3MFcM), Kc and (2MFoM3MFcM), Kc maps and then re¢ned
with X-PLOR. Subsequent manual rebuilding and water struc-
ture re¢nement throughout the protein were based on systematic
analysis of positive and negative peaks with magnitudes greater
than 2.8 c in (MFoM3MFcM), Kc maps. During re¢nement force ¢eld
energy terms were removed for atoms involved in short hydrogen
bonds. For comparison structures were superimposed based on a
set of atoms at and around the S1, S1P and active sites. Averages
and standard deviations in hydrogen bond lengths and other
parameters were calculated for multiply determined structures.
A subset of 10 structures has been deposited into the RCSB
Protein Data Bank (PDB). X-ray di¡raction and re¢nement sta-
tistics and PDB accession codes for these structures are provided
in Table 4.
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to highest resolution 20.9, 69 20.2, 69 20.3, 71 18.1, 64 19.0, 68
highest resolution shell (Aî ) 1.98^1.90 1.81^1.73 1.57^1.50 1.88^1.80 1.71^1.64
Completeness at highest resolution 27.7 33.4 36.3 31.2 34.3
Free Rccryst, to highest resolution 25.9 24.2 23.0 22.2 22.1
Protease, PDB accession code uPA, 1gja uPA, 1gjd thro, 1gj5 thro, 1gj4 tryp, 1gj6
Inhibitor, pH 7 136, 6.5 11 421, 6.5 7 806, 8.7 10 302, 9.0 10 302, 9.0
No. re£ections, Rmerge (%)a 25 786, 5.4 16 414, 9.1 26 014, 6.3 19 152, 9.6 30 523, 8.3
Rcryst, completenessb 7.0^2.00 Aî 15.9, 93 16.6, 81 17.6, 85 18.7, 68 15.0, 91
7.00^1.75 Aî 17.4, 86 17.8, 68 19.4, 71 16.6, 83
to highest resolution 18.7, 74 18.0, 68 19.7, 70 20.7, 59 18.9, 68
highest resolution shell (Aî ) 1.63^1.56 1.83^1.75 1.81^1.73 1.89^1.81 1.57^1.50
Completeness at highest resolution 31.0 30.4 32.5 30.4 29.5
Free Rccryst, to highest resolution 20.9 18.8 23.3 23.6 20.6
F/c cuto¡s ranged from 1.6 to 2.0, depending on the data-set. Root mean square deviations of bond lengths from ideality ranged from 0.015 to 0.018
Aî .
aRmerge =4h4i MI(h)i3GI(h)ifM/4h4iI(h)i .
bThe ¢rst value is the conventional R-factor (in percent), Rcryst =4(MMFoM3MFcMM)/4MFoM. The second is the overall completeness in percent.
cCross validation R-factor using 10% of the data withheld from re¢nement.
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